GlaxoSmithKline four-strain seasonal flu vaccine approved by FDA GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved FLUARIX QUADRIVALENT for the immunisation of children three years and older and adults to help prevent disease caused by seasonal influenza virus subtypes A and type B contained in the vaccine. Fluarix Quadrivalent is the first intramuscular vaccine to cover against four influenza strains, the company said. GSK will make Fluarix Quadrivalent available in time for the 2013-14 flu season and and also plans to fulfill orders for its trivalent vaccines. Healthcare providers traditionally order flu vaccines about a year in advance of each flu season, the company said.
GlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.